Carna Biosciences, Inc. announced a private placement of 24,873 19th stock acquisition rights at ¥590 per stock acquisition right for gross proceeds of ¥14,675,070 on July 14, 2021. The transaction included participation from Cantor Fitzgerald & Co. The potential shares from the issuance of stock acquisition rights will be 2,487,300 shares. The initial exercise price of stock acquisition rights ¥1,449 for a period from August 2, 2021 to August 1, 2023. The transaction will happen through third party allocation. The company will incur issuance expenses with respect to the transaction including attorney's fees, value calculation costs for the stock acquisition rights, and other administrative costs (securities registration statement preparation costs, payment handling bank fees, change registration costs, etc.).The issue date for stock acquisition rights will be July 30, 2021. The transaction has been approved at board of directors’ meeting of the company.